Review Article | Published:

Integrating oncolytic viruses in combination cancer immunotherapy

Nature Reviews Immunologyvolume 18pages498513 (2018) | Download Citation

  • A Correction to this article was published on 21 June 2018

Abstract

Oncolytic viruses can be usefully integrated into tumour immunotherapies, as they target multiple steps within the cancer–immunity cycle. Oncolytic viruses directly lyse tumour cells, leading to the release of soluble antigens, danger signals and type I interferons, which drive antitumour immunity. In addition, some oncolytic viruses can be engineered to express therapeutic genes or can functionally alter tumour-associated endothelial cells, further enhancing T cell recruitment into immune-excluded or immune-deserted tumour microenvironments. Oncolytic viruses can also utilize established tumours as an in situ source of neoantigen vaccination through cross-presentation, resulting in regression of distant, uninfected tumours. These features make oncolytic viruses attractive agents for combination strategies to optimize cancer immunotherapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

  • 21 June 2018

    In the initially published version of this article online in advance of print, a reference (Ajina, A. & Maher, J. Prospects for combined use of oncolytic viruses and CAR T-cells. J. Immunother. Cancer 5, 90 (2017)) was omitted in error from the following sentence: “The ability of oncolytic viruses to increase the expression of MHC class I molecules by cancer cells is also predicted to enhance ACT with TILs or TCR-engineered and chimeric antigen receptor (CAR) T cells that target tumour-specific antigens”. This has been corrected in the HTML and PDF versions of the manuscript.

References

  1. 1.

    Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013).

  2. 2.

    Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).

  3. 3.

    Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010). This is a randomized clinical trial demonstrating a clinical benefit of ipilimumab, the first immune checkpoint inhibitor that was approved for the treatment of melanoma.

  4. 4.

    Grosso, J. F. & Jure-Kunkel, M. N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13, 5 (2013).

  5. 5.

    Sehgal, A., Whiteside, T. L. & Boyiadzis, M. Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin. Biol. Ther. 15, 1191–1203 (2015).

  6. 6.

    Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

  7. 7.

    Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).

  8. 8.

    Andrews, A. Treating with checkpoint inhibitors — figure $1 million per patient. Am. Health Drug Benefits 8, 9 (2015).

  9. 9.

    Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).

  10. 10.

    Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T cell infiltration and PD-L1. Cancer Res. 75, 2139–2145 (2015).

  11. 11.

    Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).

  12. 12.

    Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017). This is an excellent review article describing the cancer–immunity cycle and the three different immunological tumour phenotypes.

  13. 13.

    Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017). This study investigates baseline gene expression signatures in patients who respond to PD1 therapy and establishes a T cell-inflamed gene expression signature as a predictive biomarker.

  14. 14.

    Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77, 3540–3550 (2017).

  15. 15.

    Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248–262 (2017).

  16. 16.

    Bommareddy, P. K., Patel, A., Hossain, S. & Kaufman, H. L. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am. J. Clin. Dermatol. 18, 1–15 (2017).

  17. 17.

    Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642–662 (2015). This is a comprehensive review of oncolytic viruses in clinical development and of key considerations in drug development using oncolytic virus platforms.

  18. 18.

    Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl Med. 6, 226ra32 (2014). This is one of the first research articles to report preclinical data demonstrating improved therapeutic responses using combination therapy with an oncolytic virus and an immune checkpoint inhibitor.

  19. 19.

    Thomann, S. et al. Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells. Immunology 146, 327–338 (2015).

  20. 20.

    Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240–273 (2009).

  21. 21.

    Bommareddy, P. K., Silk, A. W. & Kaufman, H. L. Intratumoral approaches for the treatment of melanoma. Cancer J. 23, 40–47 (2017).

  22. 22.

    Larocca, C. & Schlom, J. Viral vector-based therapeutic cancer vaccines. Cancer J. 17, 359–371 (2011).

  23. 23.

    Harrop, R. & Carroll, M. W. Viral vectors for cancer immunotherapy. Front. Biosci. 11, 804–817 (2006).

  24. 24.

    Haseley, A., Alvarez-Breckenridge, C., Chaudhury, A. R. & Kaur, B. Advances in oncolytic virus therapy for glioma. Recent Pat. CNS Drug Discov. 4, 1–13 (2009).

  25. 25.

    Fernandes, J. Oncogenes: the passport for viral oncolysis through PKR inhibition. Biomark Cancer 8, 101–110 (2016).

  26. 26.

    Mounir, Z. et al. Tumor suppression by PTEN requires the activation of the PKR-eIF2α phosphorylation pathway. Sci. Signal. 2, ra85 (2009).

  27. 27.

    Marsh, M. & Helenius, A. Virus entry: open sesame. Cell 124, 729–740 (2006).

  28. 28.

    Bommareddy, P. K. & Kaufman, H. L. Unleashing the therapeutic potential of oncolytic viruses. J. Clin. Invest. 128, 1258–1260 (2018).

  29. 29.

    Tuve, S. et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J. Virol. 80, 12109–12120 (2006).

  30. 30.

    Uchida, H. et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol. Ther. 21, 561–569 (2013).

  31. 31.

    Xia, T., Konno, H. & Barber, G. N. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer Res. 76, 6747–6759 (2016).

  32. 32.

    Xia, T., Konno, H., Ahn, J. & Barber, G. N. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 14, 282–297 (2016).

  33. 33.

    Vile, R. G. & Hart, I. R. Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences. Ann. Oncol. 5(Suppl. 4), 59–65 (1994).

  34. 34.

    Pelka, P. et al. Adenovirus E1A directly targets the E2F/DP-1 complex. J. Virol. 85, 8841–8851 (2011).

  35. 35.

    Savontaus, M. J., Sauter, B. V., Huang, T. G. & Woo, S. L. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther. 9, 972–979 (2002).

  36. 36.

    Cassady, K. A. & Gross, M. The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain. J. Virol. 76, 2029–2035 (2002).

  37. 37.

    Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292–303 (2003). This is the original paper describing that ICP34.5-deleted HSV-1 encoding GM-CSF has therapeutic activity in preclinical tumour models.

  38. 38.

    Deng, L. et al. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9. Oncotarget 8, 40533–40543 (2017).

  39. 39.

    Zinn, R. L., Pruitt, K., Eguchi, S., Baylin, S. B. & Herman, J. G. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 67, 194–201 (2007).

  40. 40.

    Potts, K. G., Hitt, M. M. & Moore, R. B. Oncolytic viruses in the treatment of bladder cancer. Adv. Urol. 2012, 404581 (2012).

  41. 41.

    Chung, R. Y., Saeki, Y. & Chiocca, E. A. B-Myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. 73, 7556–7564 (1999).

  42. 42.

    Singh, P. K., Doley, J., Kumar, G. R., Sahoo, A. P. & Tiwari, A. K. Oncolytic viruses and their specific targeting to tumour cells. Indian J. Med. Res. 136, 571–584 (2012).

  43. 43.

    Hu, J. C. et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12, 6737–6747 (2006).

  44. 44.

    Garg, A. D., Dudek-Peric, A. M., Romano, E. & Agostinis, P. Immunogenic cell death. Int. J. Dev. Biol. 59, 131–140 (2015).

  45. 45.

    Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, e955691 (2014).

  46. 46.

    Haag, F. et al. Extracellular NAD and ATP: Partners in immune cell modulation. Purinerg. Signal. 3, 71–81 (2007).

  47. 47.

    Gardai, S. J. et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321–334 (2005).

  48. 48.

    Bracci, L., Schiavoni, G., Sistigu, A. & Belardelli, F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21, 15–25 (2014).

  49. 49.

    Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723.e4 (2017). This study investigates a potential link between the presence of BATF3-driven DCs within the tumour microenvironment and the recruitment of effector T cells.

  50. 50.

    Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097–1100 (2008). This study shows that deletion of the transcription factor BATF3 inhibits the development of CD8α+ DCs and that cross-presentation by these cells mediates antiviral and antitumour immunity.

  51. 51.

    Brendan Horton, L. S. S. The non-T cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. Emerg. Top. Life Sci. 5, 447–456 (2017).

  52. 52.

    Dai, P. et al. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci. Immunol. 2, eaal1713 (2017).

  53. 53.

    Schmidt, S. V., Nino-Castro, A. C. & Schultze, J. L. Regulatory dendritic cells: there is more than just immune activation. Front. Immunol. 3, 274 (2012).

  54. 54.

    Kell, A. M. & Gale, M. Jr. RIG-I in RNA virus recognition. Virology 479–480, 110–121 (2015).

  55. 55.

    Cai, X., Chiu, Y. H. & Chen, Z. J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol. Cell 54, 289–296 (2014).

  56. 56.

    Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830–842 (2014). This study demonstrates that the host STING pathway is a major mechanism of innate sensing of cancers.

  57. 57.

    Mihret, A., Mamo, G., Tafesse, M., Hailu, A. & Parida, S. Dendritic cells activate and mature after infection with Mycobacterium tuberculosis. BMC Res. Notes 4, 247 (2011).

  58. 58.

    Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–820 (2010).

  59. 59.

    Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).

  60. 60.

    Wakimoto, H., Johnson, P. R., Knipe, D. M. & Chiocca, E. A. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10, 983–990 (2003).

  61. 61.

    Saha, D., Wakimoto, H. & Rabkin, S. D. Oncolytic herpes simplex virus interactions with the host immune system. Curr. Opin. Virol. 21, 26–34 (2016).

  62. 62.

    Zamarin, D. et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J. Clin. Invest. 128, 1413–1428 (2018).

  63. 63.

    Uehara, J. et al. Intratumoral injection of IFN-beta induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb. Biochem. Biophys. Res. Commun. 490, 521–527 (2017).

  64. 64.

    Cheng, X. et al. The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. J. Neuroimmunol. 185, 75–86 (2007).

  65. 65.

    DiPaola, R. S. et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J. Transl Med. 4, 1 (2006).

  66. 66.

    Zamarin, D. & Wolchok, J. D. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Mol. Ther. Oncolyt. 1, 14004 (2014).

  67. 67.

    Grekova, S. et al. Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism. J. Virol. 84, 516–531 (2010).

  68. 68.

    Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557–569 (2012).

  69. 69.

    Muller, M., Carter, S., Hofer, M. J. & Campbell, I. L. Review: the chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity — a tale of conflict and conundrum. Neuropathol. Appl. Neurobiol. 36, 368–387 (2010).

  70. 70.

    Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M. & van Hall, T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr. Opin. Immunol. 39, 44–51 (2016).

  71. 71.

    Verweij, M. C. et al. Viral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolution. PLoS Pathog. 11, e1004743 (2015).

  72. 72.

    Goldsmith, K., Chen, W., Johnson, D. C. & Hendricks, R. L. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J. Exp. Med. 187, 341–348 (1998).

  73. 73.

    Brode, S. & Macary, P. A. Cross-presentation: dendritic cells and macrophages bite off more than they can chew! Immunology 112, 345–351 (2004).

  74. 74.

    Nesslinger, N. J. et al. A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin. Cancer Res. 16, 4046–4056 (2010).

  75. 75.

    Russell, S. J. & Peng, K. W. Oncolytic virotherapy: a contest between apples and oranges. Mol. Ther. 25, 1107–1116 (2017).

  76. 76.

    Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl Cancer Inst. 109, djw261 (2017).

  77. 77.

    Woller, N. et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T cell responses. Mol. Ther. 23, 1630–1640 (2015).

  78. 78.

    Smith-Garvin, J. E., Koretzky, G. A. & Jordan, M. S. T cell activation. Annu. Rev. Immunol. 27, 591–619 (2009).

  79. 79.

    Curtsinger, J. M. & Mescher, M. F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22, 333–340 (2010).

  80. 80.

    Lapteva, N. et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol. Ther. 17, 1626–1636 (2009).

  81. 81.

    Gujar, S. A. & Lee, P. W. Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front. Oncol. 4, 77 (2014).

  82. 82.

    Gujar, S. et al. Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol. Ther. 21, 338–347 (2013).

  83. 83.

    Zamarin, D. et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat. Commun. 8, 14340 (2017).

  84. 84.

    Barber, G. N. Host defense, viruses and apoptosis. Cell Death Differ. 8, 113–126 (2001).

  85. 85.

    Petersen, J. L., Morris, C. R. & Solheim, J. C. Virus evasion of MHC class I molecule presentation. J. Immunol. 171, 4473–4478 (2003).

  86. 86.

    Su, X. et al. TNF receptor-associated factor-1 (TRAF1) negatively regulates Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF)-mediated signaling. Eur. J. Immunol. 36, 199–206 (2006).

  87. 87.

    Dorner, T. & Radbruch, A. Antibodies and B cell memory in viral immunity. Immunity 27, 384–392 (2007).

  88. 88.

    Ferguson, M. S., Lemoine, N. R. & Wang, Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv. Virol. 2012, 805629 (2012).

  89. 89.

    Bhattacharya, P. et al. Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy. J. Interferon Cytokine Res. 35, 585–599 (2015).

  90. 90.

    Tahtinen, S. et al. T-cell therapy enabling adenoviruses coding for IL2 and TNFα induce systemic immunomodulation in mice with spontaneous melanoma. J. Immunother. 39, 343–354 (2016).

  91. 91.

    Passer, B. J. et al. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther. 20, 17–24 (2013).

  92. 92.

    Uchida, H. et al. Oncolytic herpes simplex virus vectors fully retargeted to tumor- associated antigens. Curr. Cancer Drug Targets 18, 162–170 (2018).

  93. 93.

    Choi, J. W., Lee, Y. S., Yun, C. O. & Kim, S. W. Polymeric oncolytic adenovirus for cancer gene therapy. J. Control. Release 219, 181–191 (2015).

  94. 94.

    Wang, J., Lu, X. X., Chen, D. Z., Li, S. F. & Zhang, L. S. Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. World J. Gastroenterol. 10, 400–403 (2004).

  95. 95.

    Li, J. M. et al. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. Virol. J. 10, 241 (2013).

  96. 96.

    Ruiz, A. J. & Russell, S. J. MicroRNAs and oncolytic viruses. Curr. Opin. Virol. 13, 40–48 (2015).

  97. 97.

    Breitbach, C. J. et al. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19, 886–894 (2011).

  98. 98.

    Eichmann, A. & Simons, M. VEGF signaling inside vascular endothelial cells and beyond. Curr. Opin. Cell Biol. 24, 188–193 (2012).

  99. 99.

    Arulanandam, R. et al. VEGF-mediated induction of PRD1-BF1/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell 28, 210–224 (2015).

  100. 100.

    Critchley-Thorne, R. J. et al. Impaired interferon signaling is a common immune defect in human cancer. Proc. Natl Acad. Sci. USA 106, 9010–9015 (2009). This study demonstrates that interferon response genes are dysregulated in cancer cells.

  101. 101.

    Eriksson, E. et al. Activation of myeloid and endothelial cells by CD40L gene therapy supports T cell expansion and migration into the tumor microenvironment. Gene Ther. 24, 92–103 (2017).

  102. 102.

    Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015). This randomized clinical trial demonstrated a therapeutic benefit of treating patients with advanced melanoma with oncolytic HSV encoding GM-CSF; these data led to regulatory approval of this treatment in the USA, Europe and Australia.

  103. 103.

    Cheng, P. H., Wechman, S. L., McMasters, K. M. & Zhou, H. S. Oncolytic replication of E1b-deleted adenoviruses. Viruses 7, 5767–5779 (2015).

  104. 104.

    Khuri, F. R. et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879–885 (2000).

  105. 105.

    John, J. et al. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol. 11, 14 (2010).

  106. 106.

    Pfirschke, C. et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343–354 (2016).

  107. 107.

    Roulstone, V. et al. BRAF- and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. Mol. Ther. 23, 931–942 (2015).

  108. 108.

    Gholami, S. et al. Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Ther. 21, 283–289 (2014).

  109. 109.

    Diana, A. et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 7, 40992–41004 (2016).

  110. 110.

    Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).

  111. 111.

    Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S. & Bartlett, D. L. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun. 8, 14754 (2017).

  112. 112.

    Intlekofer, A. M. & Thompson, C. B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 94, 25–39 (2013).

  113. 113.

    Bourgeois-Daigneault, M. C. et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci. Transl Med. 10, eaao1641 (2018).

  114. 114.

    Kleinpeter, P. et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology 5, e1220467 (2016).

  115. 115.

    Ilett, E. et al. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene Ther. 24, 21–30 (2017).

  116. 116.

    Puzanov, I. et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34, 2619–2626 (2016).

  117. 117.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02263508 (2018).

  118. 118.

    Silk, A. W. et al. Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial [abstract]. Cancer Res. 77 (Suppl), CT026 (2017).

  119. 119.

    Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559 (2014).

  120. 120.

    Ajina, A. & Maher, J. Prospects for combined use of oncolytic viruses and CAR T-cells. J. Immunother. Cancer 5, 90 (2017).

  121. 121.

    Nishio, N. & Dotti, G. Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. Oncoimmunology 4, e988098 (2015).

  122. 122.

    Sharabi, A. B., Lim, M., DeWeese, T. L. & Drake, C. G. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16, e498–509 (2015).

  123. 123.

    Kang, J., Demaria, S. & Formenti, S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J. Immunother. Cancer 4, 51 (2016).

  124. 124.

    Ottolino-Perry, K., Diallo, J. S., Lichty, B. D., Bell, J. C. & McCart, J. A. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 18, 251–263 (2010).

  125. 125.

    O’Cathail, S. M. et al. Combining oncolytic adenovirus with radiation — a paradigm for the future of radiosensitization. Front. Oncol. 7, 153 (2017).

  126. 126.

    Kanai, R. et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J. Natl Cancer Inst. 104, 42–55 (2012).

  127. 127.

    Adusumilli, P. S. et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann. Thorac Surg. 80, 409–416 (2005).

  128. 128.

    Harrington, K. J. et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 16, 4005–4015 (2010).

  129. 129.

    Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119.e10 (2017). This study provides preliminary data from the treatment of patients with melanoma with combination therapy of T-VEC and pembrolizumab, which showed a 62% response rate and demonstrated T cell recruitment and PDL1 upregulation in the tumour microenvironment of treated melanomas.

  130. 130.

    Chesney, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. https://doi.org/10.1200/JCO.2017.73.7379 (2017).

  131. 131.

    Bommareddy, P. K., Peters, C., Saha, D., Rabkin, S. D. & Kaufman, H. L. Oncolytic herpes simplex viruses as a paradigm for the treatment of cancer. Annu. Rev. Cancer Biol. 2, 155–173 (2018).

  132. 132.

    Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847–856 (2015).

  133. 133.

    Maleki Vareki, S., Garrigos, C. & Duran, I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit. Rev. Oncol. Hematol. 116, 116–124 (2017).

  134. 134.

    Lu, Z., Zhang, C., Sheng, J., Shen, J. & Liu, B. T cell receptor beta-chain repertoire analysis reveals the association between neoantigens and tumour-infiltrating lymphocytes in multifocal papillary thyroid carcinoma. Int. J. Cancer 141, 377–382 (2017).

  135. 135.

    Pasetto, A. et al. Tumor- and neoantigen-reactive T cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol. Res. 4, 734–743 (2016).

  136. 136.

    Kloos, A., Woller, N., Gerardy-Schahn, R. & Kuhnel, F. Retargeted oncolytic viruses provoke tumor-directed T cell responses. Oncoimmunology 4, e1052933 (2015).

  137. 137.

    Dispenzieri, A. et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 31, 2791–2798 (2017).

  138. 138.

    Samson, A. et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci. Transl Med. 10, eaam7577 (2018).

  139. 139.

    Garcia-Carbonero, R. et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J. Immunother. Cancer 5, 71 (2017).

  140. 140.

    Russell, S. J. et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin. Proc. 89, 926–933 (2014).

  141. 141.

    Jiang, H. et al. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7, 48–56 (2005).

  142. 142.

    Kanai, R. et al. Effect of gamma34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J. Virol. 86, 4420–4431 (2012).

  143. 143.

    Reinboth, J. et al. Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates. Hum. Gene Ther. Methods 23, 285–296 (2012).

  144. 144.

    Wollmann, G., Rogulin, V., Simon, I., Rose, J. K. & van den Pol, A. N. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J. Virol. 84, 1563–1573 (2010).

  145. 145.

    Dobrikova, E. Y. et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol. Ther. 16, 1865–1872 (2008).

  146. 146.

    Allen, C. et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin. Biol. Ther. 8, 213–220 (2008).

  147. 147.

    Zamarin, D. & Palese, P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 7, 347–367 (2012).

  148. 148.

    Nakaya, T. et al. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 75, 11868–11873 (2001).

Download references

Acknowledgements

The authors thank R. Coffin for review of the manuscript and helpful comments and suggestions.

Author information

Affiliations

  1. Rutgers Graduate School of Biomedical Sciences, New Brunswick, NJ, USA

    • Praveen K. Bommareddy
  2. Dana-Farber Cancer Institute, Boston, MA, USA

    • Megha Shettigar
  3. Replimune, Inc., Woburn, MA, USA

    • Howard L. Kaufman
  4. Massachusetts General Hospital, Boston, MA, USA

    • Howard L. Kaufman

Authors

  1. Search for Praveen K. Bommareddy in:

  2. Search for Megha Shettigar in:

  3. Search for Howard L. Kaufman in:

Contributions

P.K.B. and H.L.K. researched data for the article; P.K.B., M.S. and H.L.K. contributed to discussion of content and to writing the article; and P.K.B. and H.L.K. reviewed and edited the article before submission.

Competing interests

H.L.K. is an employee of Replimune, Inc. The remaining authors declare no competing interests.

Corresponding author

Correspondence to Howard L. Kaufman.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41577-018-0014-6